Formulation and Evaluation of Oral Disintegrating Tablets of Lamotrigine Solid Dispersions Oral dispersible tablets
Iranian Journal of Pharmaceutical Sciences,
Vol. 9 No. 1 (2013),
6 February 2024
,
Page 1-12
https://doi.org/10.22037/ijps.v9.40908
Abstract
Lamotrigine is used in the treatment of CNS disorders, particularly epilepsy; pain; oedema; multiple sclerosis and psychiatric indications including bipolar disorder. Lamotrigine belongs to biopharmaceutical classification systems; BCS class II (Low solubility & High permeability). In addition, it requires immediate therapeutic action. Hence, the main objective of this study is to improve the solubility by solid dispersion technique and formulate it as oral disintegrating tablets (ODT) to avert the problems of swallowing and to provide rapid onset of action. Lamotrigine solid dispersion was prepared by using Tween 80 and Gelucire 44/14 as solubility enhancers and formulated it into ODT by direct compression technique using different concentrations of Kyron T-314, Kyron T-154, and Kyron T-104 as cross linked polymers. The tablets were evaluated for various parameters and the results were found to be satisfactory. The batches of LMTK314 (2), LMGK314 (2) were selected as optimized batch containing Kyron T-314 as super disintegrant in 2% concentration, as they showed 100% drug release in 8 minutes and 6 minutes with a disintegration time of 11 and 9 seconds respectively. Upon comparison of dissolution profiles of optimized formulae LMTK314 (2), LMGK314 (2) with a marketed product, it proved that the optimized formulae had shown better dissolution. The optimized formulations were subjected to stability studies for three months as per ICH guidelines and showed physical stability with insignificant change in the hardness, disintegration time, drug content and in vitro drug release.
- Fast dissolving tablets
- Gelucire 44/14
- Kyron
- Lamotrigine
- ODT
- Solid dispersion technique
- Solubility enhancers
- Super disintegrant
- Tween 80.
How to Cite
References
[2] Deveswaran R, Sravya S, Bharath, B, Madhavan V. Development of modified porous starch as a carrier to improve aqueous solubility. Advances in Applied Science Research, 2012, 3:162-170.
[3] Magda TM, Clésio SP, Martin S. Development of a dissolution test for lamotrigine in tablet form using an ultraviolet method. Brazilian Journal of Pharmaceutical Sciences, 2010, 46:180-186.
[4] Venkat BY, Adhikrao VY . Enhancement of solubility and dissolution rate of bcs class ii pharmaceuticals by nonaquious granulation technique. International journal of pharma research and development-online, 2010,1.
[5] Mudgal VK, Pooja S, Rajat K, Saraogi GK, Singhai A K. Orally disintegrating tablets: review. Intenational journal of pharmacy, 2011, 2:16-22.
[6] Chowdary KPR, Srinivasa R. Investigation of dissolution enhancement of itraconazole by solid dispersion in superdisintegrants. Drug Dev. Ind. Pharm, 2000, 26:1207-11.
[7] Gohel M, Patel M, Amin A, Agarwal R, Dave R, Bariya N. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS Pharm.Sci.Tech, 2004, 5:1-6.
[8] United States Pharmacopoeia. Rockville: USP Convention, Inc; 2004 ; 2302.
[9] Magesh KM, Antaryami J, Ruckmani K, Rajen dran P. Formulation and evaluation of taste masked orally disintegrating ondansetron hydrochloride tab let. Int. J. Res. Pharm. Sci, 2010, 1:328-332.
[10] Dressman J and Kramer J, Eds., Pharmaceutical Dissolution Testing. USA,2005; 91-93.
[11] Kiran T, Nalini S, Ramakrishna S, Sadanandam M. Surface solid dispersion of glimepiride for enhancement of dissolution rate. International Journal of PharmTech Research, 2009, 1:822-31.
[12] Yang KY, Glemza R, Jarowski CI. Effects of amorphous silicon dioxides on drug dissolution. J. Pharm. Sci, 1979,68:560-5.
[13] European Pharmacopoeia.Strasbourg (France): European department for the quality of medicines. 2001;1666–9.
[14] Yusuke S, Makiko F, Hideko O, Shinobu N,Masuo K, Yoshiteru Watanabe. Evaluation of the compaction properties of a solid dispersion of indomethacin with crospovidone by tableting process analyzer. Chemical & pharmaceutical bulletin, 2005, 53:759.
[15] Raymond CR, Paul JS, Marian E Quinn, Eds., Handbook of pharmaceutical excipients,6th edition, 2009; London, Pharmaceutical Press. 206-210,424-428,404-407,185-188,48-50,129-133, 504-506.
- Abstract Viewed: 572 times
- drlakshmisuresh@gmail.com Downloaded: 391 times